Type 1 diabetes mellitus and Apidra


Type 1 Diabetes Mellitus Symptoms and Causes

Diabetes means your blood glucose, or blood sugar, levels are too high. With type 1 diabetes, your pancreas does not make insulin. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth.

Type 1 diabetes happens most often in children and young adults but can appear at any age. Symptoms may include

  • Being very thirsty
  • Urinating often
  • Feeling very hungry or tired
  • Losing weight without trying
  • Having sores that heal slowly
  • Having dry, itchy skin
  • Losing the feeling in your feet or having tingling in your feet
  • Having blurry eyesight

A blood test can show if you have diabetes. If you do, you will need to take insulin for the rest of your life. A blood test called the A1C can check to see how well you are managing your diabetes.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for type 1 diabetes mellitus

type 1 diabetes mellitus treatment research studies

Apidra clinical trials, surveys and public health registries

Find Drug Side Effect reports

Apidra Side Effects

Blood Glucose Increased (210)
Hyperglycaemia (99)
Hypoglycaemia (89)
Product Quality Issue (63)
Blood Glucose Decreased (59)
Malaise (40)
Diabetic Ketoacidosis (37)
Dizziness (34)
Dyspnoea (31)
Nausea (27)
Headache (26)
Vision Blurred (25)
Hypoglycaemic Unconsciousness (23)
Feeling Abnormal (23)
Fall (22)
Vomiting (21)
Asthenia (21)
Fatigue (19)
Weight Increased (18)
Diabetes Mellitus Inadequate Control (18)
Chest Pain (17)
Confusional State (17)
Pruritus (17)
Weight Decreased (17)
Visual Impairment (16)
Loss Of Consciousness (16)
Death (16)
Glycosylated Haemoglobin Increased (16)
Hyperhidrosis (15)
Oedema Peripheral (15)
Pain (14)
Pain In Extremity (14)
Diarrhoea (14)
Hypoglycaemic Coma (13)
Cerebrovascular Accident (13)
Overdose (13)
Ketoacidosis (11)
Myocardial Infarction (11)
Hypersensitivity (11)
Cataract (11)
Blood Pressure Increased (11)
Abdominal Pain Upper (11)
Decreased Appetite (10)
Cough (10)
Dehydration (10)
Glaucoma (10)
Hypertension (10)
Injection Site Pain (9)
Rash (9)
Myalgia (9)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

After using Apidra for two months, I am experiencing the following symptoms- anxiety, shakiness, rash over body, digestive tract disturbance and fainting spells. I am discontinuing my use of Apidra due to these side effects and will return to Humalog

I have felt bad for about a month, tired, nauseated, muscle cramps, sweating, fever, headache, low sodium, urinary and kidney infection, trouble sleeping, heart palpitations. I had blood test done doctors could not find anything wrong, I have had col

I have not used apidra but am interested in its use in insulin pump and its benefits


Hello, I was given Azastin or Avastin for macular edema. I also have retinopathy from diabetes. I was given this shot in my eye in April of this yr. Within 2 days, I had cellulitis in both legs. Horrible pain. Dark red all over from my knees to my

Hi! am looking Operational and Installation manual for this type of x-ray machine Summit AmeriComp control console, with power module SHF 310 and other accessories of it. Well! let me give you this control console picture may be you will aware of


sorry type errors if i could do it over i would have never taken this drug if i had only know .. wahtever you do don't just trust your doctor is doing the right thing or even a good thing for you like i did do

My grand father was diagnosed with dementiaalzheimer's type and was prescribed Aricept. After he started taking Aricept, his condition have gotten worse and he actually died yesterday. He was 83 years old.

<span style='color: #808080;'><b>Describe Your Henoch-Schonlein purpura from INFLUENZA (H1N1) (H1N1 (MONOVALENT) SANOFI) 2010 Experience Here:</b> Vicious headaches, rash on legs and trunk, transient, cystitis type fee

After being exposed to bright light my vision field is spotty with bright lights. I have a similar experince when I'm hypoglycemic often my first sympto but this type is unrelated to my BLOOD SUGAR. mY LATEST MEDS ADDED ARE Cardizem for A-fib, coumad

After just 7 days of starting pioglitazone(15 mg.daily) ,I developed loss of taste for mainly sugar and salt,but unfortunatyely i couldnot guess pioglitazone as possible cause. I am type 2 diabetic and hypertensive and taking metformin,glimeperide,li

After taking 500mg of fortamet for two weeks i am having blured vision . i am type 2 diabetic.

Another thing, can a patient with diabetes type 1 and previously suffered and recovered from Multiple sclerosis ( M-S ) use Spasfon ???

Type 1 Diabetes Mellitus Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010);   Drug: insulin glulisine (HMR1964)
Outcome Measures: Change from baseline in HbA1c;   Change from baseline in body weight;   Percentage of patients reaching HbA1c <7%;   Percentage of patients reaching HbA1c ≤6.5%;   Change in body weight from baseline;   Percentage of patients with no weight gain;   Change in 7-point SMPG profiles from baseline;   Change from baseline in FPG;   Change from baseline in post-prandial glucose /glucose excursions during a standardized meal test (subset of patients);   Change from baseline in insulin glargine dose;   Daily dose of insulin glulisine;   Total daily dose of insulin;   Documented (PG <60 mg/dl) symptomatic hypoglycemia (percentage of subjects with at least one episode, number of events per patient-year);   Severe hypoglycemia
2 Recruiting Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
Condition: Diabetes During Pregnancy
Interventions: Drug: NPH;   Drug: Insulin LISPRO;   Drug: Insulin glulisine
Outcome Measures: show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus;   Serum blood glucose area under the curve (AUC) at one 4-hour in-clinic meal challenge;   Compare A1C at enrollment and weekly until delivery;   Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms
3 Recruiting Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glulisine;   Drug: Insulin aspart
Outcome Measures: Postprandial glycemia;   Hypoglycemia episodes;   Glucose Area Under the Curve (AUC);   Mean amplitude of glycemic excursion (MAGE);   Difference between the maximum and baseline glycemia
4 Unknown  Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
Condition: Insulin-requiring Type 2 Diabetes Mellitus
Interventions: Drug: nph insulin;   Drug: human insulin;   Drug: Insulin Glargine;   Drug: Insulin glulisine
Outcome Measures: Fasting Intact Proinsulin;   Weight;   hsCRP;   Adiponectin;   MMP-9;   OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes after 24 weeks;   HOMA-IR score;   HbA1c;   Fasting intact Proinsulin;   Glucose;   Responder rate;   Hypoglycemic events.
5 Unknown  Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
Condition: Type 1 Diabetes
Intervention: Device: Diabetes Interactive Diary (DID)
Outcome Measures: Blood levels of glycosylated hemoglobin;   blood glucose (BG) levels;   Glucose variability;   Change in body weight and BMI;   Total daily insulin dose, total basal insulin dose, total prandial insulin dose;   Quality of life;   Frequency of patients with hypoglycemic episodes and frequency of hypoglycemic episodes overall;   Frequency of patients with severe and/or symptomatic hypoglycemia and frequency of severe and/or symptomatic hypoglycemic episodes overall;   Frequency and times of hypoglycemic events with regard to occurrence during the day (24 hours) and total treatment duration (24 weeks)
6 Recruiting Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901);   Drug: INSULIN GLULISINE (HMR1964)
Outcome Measures: Changes in Hemoglobin A1c (HbA1c) level;   Rate of hypoglycemia;   Changes in insulin glargine dose;   Changes in insulin glulisine dose
7 Recruiting Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes
Condition: Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy
Interventions: Drug: LEVEMIR;   Drug: Apidra
Outcome Measures: Mixed measurement of insulin secretion and insulin resistance;   Decrease in the time spent in baseline and prandial hyperglycemia
8 Recruiting Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Conditions: Type 2 Diabetes;   Renal Insufficiency
Intervention: Drug: Glargine & glulisine
Outcome Measures: To determine if a glargine based regime with dose reduction for renal insufficiency is more efficacious than a glargine regime without such a reduction in hospitalized patients.;   To determine the relative safety of each of the regimes in avoidance of hypoglycemia.
9 Recruiting TReatment by Insulin Continuous Infusion in Type 2 DIAbetes
Condition: Diabetes
Intervention: Drug: 2 different procedures of administration of insulin
Outcome Measures: changes from baseline in insulinoresistance measured by biological tests of hyperinsulinemic euglycemic clamp in the two groups of treatment 6 months after the start of the treatment.;   change from baseline in the hyperglycemia time spent during basal and prandial period with continuous glucose monitoring tool at 6 months;   change from baseline in HbA1c in the two groups of treatment at three, six, nine and twelve months;   change from baseline in quality of life measured with questionnaires at 6 months;   change from baseline in weight at three, six, nine and twelve months in the two groups.
10 Unknown  Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards
Condition: Diabetes Mellitus Type 2
Interventions: Drug: regular insulin;   Drug: Insulin glulisine, Insulin glargine
Outcome Measure:
11 Unknown  Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
Conditions: Type 2 Diabetes;   Liver Cirrhosis
Interventions: Drug: Glargine & Glulisine;   Drug: Regular insulin;   Drug: NPH & regular insulin
Outcome Measures: optimal glycemic control in inpatient cirrhotics;   Incidence of hypoglycemic episodes
12 Recruiting The Differential Effects of Diabetes Therapy on Inflammation
Conditions: Diabetic Nephropathy;   Type 2 Diabetes
Interventions: Drug: Insulin, Long-Acting;   Drug: Dipeptidyl-Peptidase IV Inhibitors;   Drug: Glucagon-Like Peptide 1
Outcome Measures: Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio;   Albumin:creatinine ratio
13 Recruiting Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft(CABG) Patients
Condition: Poor Glycemic Control
Interventions: Drug: metformin;   Drug: Glargine+ metformin;   Drug: Metformin+glargine+aspart
Outcome Measures: blood glucose;   hemoglobin A1c;   hypoglycemia;   severe hyperglycemia;   severe hypoglycemia;   readmissions;   emergency room visits;   Postoperative complications